



By Carolyn Gretton

► PHARMACEUTICAL POOL

Greg IRACE

Anne WHITAKER

SANOFI SHIFTS U.S. LEADERSHIP



Sanofi has named Greg Irace senior VP, global services. Mr. Irace leads the global information systems function and is responsible for shared support functions across all Sanofi businesses in North America.

He also plays a key role in the development of a global strategy for shared services. Mr. Irace was previously president and CEO of Sanofi's U.S. operations.

In a related move, Anne Whitaker has joined Sanofi as president, North America, pharmaceuticals. Ms. Whitaker was most recently GlaxoSmith-Kline's senior VP and business unit head, cardiovascular, metabolic, and urology.

► BIOPHARMACEUTICAL POOL

Dr. Sean DALZIEL

Helen JENKINS

TOBIRA MAKES KEY MANAGEMENT ADDITIONS



Tobira Therapeutics has added two VPs to its leadership roster as the biopharmaceutical company advances cenicriviroc, its lead product candidate for the treatment of HIV infection, through Phase II clinical studies and prepares for a Phase III program.



Sean Dalziel, Ph.D., has joined Tobira as VP, pharmaceutical development. Dr.

Dalziel was most recently with Onyx Pharmaceuticals, where he was the company representative to the FDA and other global health authorities on CMC sections for all pipeline programs and conducted CMC due diligence in support of business development activities.

He received a Ph.D. in chemical engineering from the University of Queensland in Australia and an MBA from the Haas School of Business at the University of California, Berkeley.

Helen Jenkins has been appointed senior VP, program leadership. Ms. Jenkins was most recently with Nuon Therapeutics and Saegis Pharmaceuticals, where as a corporate officer she was responsible for development operations, strategic planning, and portfolio management.

She holds an M.A. in cellular and molecular biology from San Francisco State University.

► SPECIALTY POOL

Dr. Kenneth BAHRT

SAVIENT TAPS FORMER GENENTECH EXECUTIVE AS MEDICAL CHIEF



Savient Pharmaceuticals has named Kenneth Bahrt, M.D., chief medical officer, responsible for leading the overall management of the specialty pharmaceutical company's clinical development, drug safety, and medical affairs teams.

Dr. Bahrt, a board-certified rheumatologist, joins Savient from Genentech, where he most recently served as therapeutic area head for U.S. medical affairs (immunology).

Dr. Sandra CROAK-BROSSMAN

BIOSANTE ADDS VP



BioSante Pharmaceuticals, a specialty pharmaceutical company focused on developing products for female sexual health and oncology, has appointed Sandra Croak-Brossman, Ph.D., VP, regulatory affairs and quality assurance. Dr. Croak-Brossman has more than 24 years of experience in the pharmaceutical industry, including positions at Boehringer Ingelheim, Pfizer, and Abbott Laboratories.

She earned an M.S. and a Ph.D. in quantitative genetics and animal breeding from Purdue University.

Dr. Ramona LLOYD

OMTHERA APPOINTS REGULATORY VP



Privately held specialty pharmaceuticals company Omthera Pharmaceuticals has named Ramona Lloyd, Ph.D., VP, regulatory affairs. Dr. Lloyd's responsibilities include the management of regulatory strategy and interactions with the FDA as the company prepares for anticipated regulatory filings for Epanova, a triglyceride-lowering adjunct therapy to diet in patients with high triglycerides.

Dr. Lloyd previously served as VP, regulatory affairs for Ethicon, a Johnson & Johnson company. She is regulatory affairs certified and holds a Ph.D. in molecular genetics and microbiology from Rutgers University and the University of Medicine and Dentistry of New Jersey.

Dr. Elizabeth OLEK

ACHILLION PROMOTES MEDICAL CHIEF

Achillion Pharmaceuticals, a company focused on



the discovery and development of small-molecule drugs to combat the most challenging infectious diseases, has promoted Elizabeth Olek, D.O., to senior VP of clinical development and chief medical officer, from VP of clinical development and chief medical officer.

► DIAGNOSTIC POOL

Mara ASPINALL

VENTANA APPOINTS PRESIDENT



Ventana Medical Systems, a member of the Roche Group that innovates and manufactures instruments and reagents for automating tissue processing and slide staining for cancer diagnostics, has named Mara Aspinall president.

Ms. Aspinall was most recently founder, president, and CEO of On-Q-ity. In addition, she was a member of the Secretary of Health and Human Services' former Advisory Council on Genetics and is a co-founder of the European Personalized Medicine Association. Ms. Aspinall received an MBA from Harvard Business School.

Dennis FLANNELLY

THERMO FISHER APPOINTS MARKETING HEAD



Dennis Flannely has been appointed head of marketing and strategy for Thermo Fisher Scientific's immunodiagnosics division, formerly known as Phadia. Mr. Flannely's responsibilities include overseeing all marketing efforts for ImmunoCAP in vitro allergy testing products.

Mr. Flannely joins Thermo Fisher Scientific from Merck, where he rose from field sales to lead U.S. and international product launch planning within franchises such as migraine and insomnia. Mr. Flannely received a master's degree in marketing from St. Joseph's University.

John LUBNIEWSKI

HTG MOLECULAR DIAGNOSTICS APPOINTS BUSINESS CHIEF



John Lubniewski has joined HTG Molecular Diagnostics as chief business officer. Mr. Lubniewski is responsible for leading the sales, marketing, and product development teams for HTG's three strategic business areas: molecular testing capabilities for translational medicine, pharmaceu-

tical clinical development, and pathology laboratory diagnostics.

Mr. Lubniewski previously held multiple senior management positions at Ventana Medical Systems, including life-cycle leader of advanced staining platforms and senior VP of clinical assays.

► ASSOCIATION POOL

Dr. Timothy COTÉ

NORD NAMES MEDICAL CHIEF



Timothy Côté, M.D., has joined the National Organization for Rare Disorders (NORD) as chief medical officer. Dr. Côté is providing medical guidance in all areas — particularly advocacy and education — to promote fair, compassionate public policies; encourage the development of safe, effective treatments; and increase awareness of rare diseases and the needs of patients and their families.

Dr. Côté was previously director of the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA). He received an MPH from Harvard School of Public Health and an M.D. from Howard University College of Medicine.

► AGENCY POOL

Erin ABBOTT

Kiersten DUFFEY

Courtney MASON

ABELSONTAYLOR ANNOUNCES PROMOTIONS



Independent healthcare advertising agency AbelsonTaylor has made several promotions within its account services group.



Erin Abbott has been promoted to senior account executive, from account executive. Ms. Abbott is in charge of all digital and e-marketing initiatives for a pain medication.



Kiersten Duffey has been elevated to account executive, from account coordinator. Ms. Duffey is working on the launch of a new product for the treatment of lupus, in addition to continuing her work on products in the areas of women's health and epilepsy.

Courtney Mason has been promoted to senior

account planner, from account planner. Ms. Mason is managing infant nutrition and medical device accounts.

Matt BALOGH

Jeff BRATTESON

Colleen BRIGGS

Jodi CEBERIO

Clare LITZ

Annie LOCK

Lori THOMPSON

OGILVY COMMONHEALTH MAKES STAFF CHANGES



Ogilvy CommonHealth Worldwide has announced a number of promotions and additions to staff at several of its agencies.



Matt Balogh has joined Ogilvy CommonHealth Interactive Marketing as VP, director of technology. Mr. Balogh was most recently VP, director of technology at MRM Worldwide.



Jeff Bratteson has joined Ogilvy Healthworld as creative director, charged with leading his assigned creative teams, building client relationships, and directing new business opportunities. Mr. Bratteson was previously the owner of Leap Design, a creative agency that specialized in online, print, and direct marketing.



At Ogilvy Healthworld, Colleen Briggs has been promoted to senior partner, head of planning, from senior partner, planning director. Ms. Briggs is responsible for overseeing strategic planning, digital strategy, and applied science initiatives for all of her assigned brands and direct new business opportunities.



Ogilvy CommonHealth Specialty Marketing has appointed Jodi Ceberio VP, account group supervisor, serving as the healthcare professional lead for her designated accounts and providing strategic and tactical insights for her team. Before joining the company, Ms. Ceberio was a VP, account group supervisor at UCB.

Clare Litz has returned to Ogilvy CommonHealth Medical Marketing as a VP, associate creative director, working with senior art personnel to ensure the creation and presentation of consistent strategies and creative communications, as well as assisting with client relationship development and expansion for the agency. Ms. Litz had previous stints within the organization as a copy supervisor and freelance copy consultant. Immediately be-

fore rejoining Ogilvy CommonHealth, Ms. Litz worked as group copy supervisor at Torre Lazur McCann.

Annie Lock has rejoined Ogilvy CommonHealth Medical Marketing as senior VP, management, serving as lead across multiple accounts to create new business opportunities and build strong client relationships. Ms. Lock started her career with the organization in the late 1990s as an account manager. Immediately before rejoining Ogilvy CommonHealth, Ms. Lock was a senior VP, management supervisor at Euro RSCG Life Catapult.

Also at Ogilvy CommonHealth Medical Marketing, Lori Thompson has been appointed VP, account group supervisor, responsible for strategic planning, development, and implementation of her assigned projects. Ms. Thompson was most recently VP, director at Franklyn Healthcom.

Nick BARTOLOMEO

Whitney BROSTROM

Muir PALMER

Carly (Postel) POVILAITIS

Jen ROGERS

Melissa SHUSTERMAN

Scott SZEWCZAK

CADIENT CONTINUES STAFF GROWTH



Cadient Group, a provider of digital marketing services and technology-enabled solutions for the healthcare industry, has announced a number of new additions to its King of Prussia, Pa., and New York offices.



Nick Bartolomeo has been named a strategic engagement director in Cadient's King of Prussia office. Mr. Bartolomeo was previously VP of strategy at Annodyne.



Whitney Brostrom has been named an account manager in the King of Prussia office. Muir Palmer joins Cadient's New York office as a strategic engagement director. Ms. Palmer was previously an account director at Eveo.



Carly (Postel) Povilaitis and Jen Rogers have joined the King of Prussia office as account managers. Also in King of Prussia, Melissa Shusterman has been named manager, web analytics, and Scott Szewczak has been appointed manager of insights solutions, Reveal, Cadient's insights and analytics suite.



Michael DU TOIT
Dr. Michael GOLUB
Matt MCNALLY
Alexandra VON PLATO

DIGITAS, RAZORFISH FORM GLOBAL EXECUTIVE TEAM



Sister healthcare marketing agencies Digitas Health and Razorfish Health have announced two executive-level promotions and the formation of a global executive team.



Michael du Toit has been named global co-president of Digitas and Razorfish. Mr. du Toit retains his role as chief marketing officer and also serves on the new global executive team. He was executive VP serving as marketing and client service lead since 2006.

Chief Medical Officer Michael Golub, M.D., has also been appointed to the global executive team, along with Matt McNally, chief media officer.

Alexandra von Plato has been promoted to global co-president of Digitas and Razorfish, in addition to her existing role as chief creative officer. Ms. von Plato, who also has joined the global executive team, was previously executive VP and chief creative officer.

Seth HOUSTON
Gabriel NERO

TWO VPS JOIN HEALTHCARE REGIONAL MARKETING



Healthcare Regional Marketing (HRM), a marketing services company specializing in pharmaceutical regional marketing solutions, has appointed two seasoned pharmaceutical executives to its leadership team.



The company has appointed Seth Houston VP of innovation and product development. Mr. Houston most recently served as senior director of product marketing at Wolters Kluwer Pharma Solutions.

Gabriel Nero has joined HRM as VP of healthcare markets. Previously, Mr. Nero was VP, group account supervisor, at Euro RSCG Life Catapult.

R. Steven LANG

ACC APPOINTS CLIENT SERVICES VP



Medical and scientific communications company Advanced Clinical Concepts (ACC) has named R. Steven Lang senior VP, client services, overseeing client accounts and new business

development. Mr. Lang has more than 36 years of healthcare experience on both the client and agency sides, including stints at Johnson & Johnson and Wyeth.

Haeri LEE
Lynn PAOLICELLI
Heather WAGONER

DUDNYK MAKES ADDITIONS, PROMOTIONS



Independent, multichannel pharmaceutical agency Dudnyk has announced a number of additions and promotions to its team.



Haeri Lee has been promoted to account executive. After completing a full year at Dudnyk, Ms. Lee has assumed additional responsibilities on the Merck account and serves as the primary client contact for four Merck brands.



Lynn Paolicelli has joined Dudnyk as VP, director of digital strategy. Ms. Paolicelli's primary responsibility is optimizing multichannel marketing opportunities for all client content. She was previously VP, account director for Blue Diesel.

Heather Wagoner was promoted to senior account executive after two years at Dudnyk. Ms. Wagoner is responsible for all day-to-day client services for AMAG Pharmaceuticals and Medtronic.

David LOWE

CHANDLER CHICCO HIRES CREATIVE DIRECTOR



'nition Design, a Chandler Chicco company and health-focused design agency, has appointed David Lowe creative director/advertising lead. Mr. Lowe is focusing on corporate and direct-to-consumer advertising, PSA development, and creative direction.

Before joining 'nition Design, Mr. Lowe spent more than seven years directing the U.S. marketing efforts for Austrian ski manufacturer Fischer.

Leah MONTEIRO

LAVOIE STRENGTHENS ACCOUNTS TEAM



Life-sciences and pharmaceutical communications provider LaVoie Group has appointed Leah Monteiro senior account executive. Ms. Monteiro was previously senior manager in corporate communications and investor relations for Genzyme.

Kent SEWELL

PACIFIC COMMUNICATIONS NAMES COPY SUPERVISOR



Davis & Mann.

Healthcare communications agency Pacific Communications has appointed Kent Sewell copy supervisor with the Restasis creative team. Mr. Sewell was previously a senior copywriter at Cline

Maria WOODS

PUBLICIS TOUCHPOINT ADDS TO COMPLIANCE TEAM



Publicis Touchpoint Solutions, a division of Publicis Healthcare Communications Group and provider of multichannel message delivery solutions for the life-sciences industry, has appointed Maria Woods director, compliance and privacy. Ms. Woods was most recently VP, legal, regulatory, and professional affairs with the Greater New York Hospital Association. She received a J.D. from City University of New York School of Law.

► **CONSULTING POOL**

Richard MARTIN

KANTAR HEALTH NAMES ONCOLOGY CHIEF



Kantar Health, a healthcare-focused global consultancy and marketing insights company, has appointed Richard Martin to the position of CEO, Kantar Health Oncology. Mr. Martin was previously Kantar's CEO, global practices.

Troy NORRIS

QUINTILES CONSULTING TAPS HEAD OF PRODUCT DEVELOPMENT PRACTICE



Quintiles Consulting, a Quintiles business, has appointed Troy Norris VP and managing director for its product development and commercialization practice. Mr. Norris is focusing on portfolio strategy and management, clinical transformation, asset valuation, and transactions for the practice.

Mr. Norris previously held senior positions in the life-sciences practices of a number of strategy consulting firms, including McKinsey, L.E.K. Consulting, and Trinity Partners.

He received an MBA from Harvard Business School.

► CRO POOL

Dr. Vadim **KLYUSHNICHENKO**

PARAGON APPOINTS PRECLINICAL VP



Paragon Bioservices, a contract research and GMP manufacturing organization, has named Vadim Klyushnichenko, Ph.D., VP, preclinical services and process development. Dr. Klyushnichenko has more than 15 years of experience in biopharmaceutical project management, analytical development and formulation, process development, engineering, and scale-up from pilot to GMP manufacturing, technology transfer, and regulatory filing.

Dr. Klyushnichenko received an M.S. in engineering from Moscow Institute of Physics and Technology and a Ph.D. in chemistry from Shemyakin Institute of Bioorganic Chemistry in Moscow.

Dr. George **SCOTT**

FORMER AMGEN DIRECTOR JOINS PHARMANET



PharmaNet Development Group, an Inventiv Health company and provider of clinical development services to pharmaceutical, biotechnology, generic drug, and medical device companies, has appointed George Scott, Ph.D., VP, bioanalytical services.

Dr. Scott provides leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the United States and Canada and leads the company's geographical and service expansion strategies in bioanalysis.

Dr. Scott most recently served as director of pharmacokinetics and drug metabolism for Amgen. He received a Ph.D. for studies in neuropharmacology from the University of Nottingham in the United Kingdom.

Meghann **SMITH**

OCKHAM APPOINTS SENIOR DIRECTOR



Ockham, a global, full-service contract research organization with a focus in oncology, has named Meghann Smith senior director, global therapeutic strategic development within its OckhamCRO division.

Ms. Smith most recently was with PPD, where she implemented senior-level program management oversight and risk mitigation strategies in all phases of study development.

Dr. Jeffrey **SPAEDER**

QUINTILES ANNOUNCES NEW MEDICAL/SCIENTIFIC CHIEF



Quintiles has appointed Jeffrey Spaeder, M.D., chief medical and scientific officer, succeeding Dr. Oren Cohen, who now leads Quintiles' Phase I clinical research business.

Dr. Spaeder's responsibilities include providing leadership on the ethical conduct of studies and serving as Quintiles' lead medical expert representing the CRO's position on a wide variety of governance, ethical, and scientific issues.

Before joining Quintiles, Dr. Spaeder was executive director of global medical affairs for Takeda Pharmaceuticals International.

He is a graduate of the Johns Hopkins University School of Medicine and holds an MBA with a concentration in finance from Northwestern University.

Dr. Mark **SUTO**

SOUTHERN RESEARCH NAMES DRUG DISCOVERY VP



Nonprofit scientific research organization Southern Research Institute has named Mark Suto, Ph.D., VP of its drug discovery division. Dr. Suto and his team are focusing on basic research and target identification and lead discovery, as well as optimization of new therapies for cancer, infectious diseases, and neurological diseases and disorders.

Dr. Suto joins Southern Research from Icagen, where he served as VP of chemical and pharmaceutical sciences. He received a Ph.D. from the University at Buffalo, part of the State University of New York system.

► SERVICE POOL

Kyu **OM**

MTI APPOINTS BUSINESS DEVELOPMENT HEAD



MTI, a supplier of strategic resource allocation and campaign management services for the biopharmaceutical industry, has named Kyu Om VP, business development, responsible for promoting MTI's proprietary DCS marketing platform and using his experience in multichannel marketing strategies to develop new client opportunities. Mr. Om was previously director of business development for SDI.

John **PARSONS JR.**

PDI SELECTS HEAD OF INTERPACE BUSINESS



PDI has named John Parsons Jr. senior VP and general manager of Interpace BioPharma, a subsidiary formed to manage full product commercialization opportunities. Mr. Parsons was previously president and chief commercial officer of the U.S. division of Denmark's TopoTarget. PDI is a healthcare commercialization company providing integrated multichannel message delivery to established and emerging healthcare companies.

Dan **THOMAS**

OMNICARE SELECTS GENERAL MANAGER FOR RXCROSSROADS BUSINESS



Omnicare has appointed Dan Thomas senior VP and general manager, Rx-Crossroads, a core business unit of Omnicare's Specialty Care Group. Mr. Thomas has full operational responsibility for RxCrossroads, a provider of specialized solutions specifically tailored to the biotechnology and pharmaceutical industries. Mr. Thomas was most recently VP of distribution operations.

► TECHNOLOGY POOL

Joe **AMOROSO**

QFORMA APPOINTS CLIENT SERVICES DIRECTOR



Qforma, a provider of advanced analytics and predictive modeling technologies for the health sciences industry, has named Joe Amoroso director, client services. Mr. Amoroso joins Qforma from UCB, where he led field sales teams throughout the eastern U.S. He received an MBA in finance from Rochester Institute of Technology.

Eileen **MARTINSON**

SPARTA SYSTEMS NAMES CEO



Sparta Systems, a provider of enterprise quality and compliance management solutions, has named Eileen Martinson to succeed James McGowan as CEO. Ms. Martinson joins Sparta from Allscripts. **PV**

Allscripts. **PV**



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV1011-Pool



► PHARMACEUTICAL POOL

Dr. Michael KITT

PORTOLA NAMES MEDICAL CHIEF

Michael Kitt, M.D., has joined Portola Pharmaceuticals as senior VP and chief medical officer. Portola discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular and autoimmune/inflammatory diseases.

Dr. Kitt most recently served as executive VP and chief medical officer for Nuon Therapeutics. He received an M.D. from NYU School of Medicine.

► BIOTECHNOLOGY POOL

Dr. Ashok AMIN

ADVAXIS NAMES R&D VP

Advaxis, a developer of next-generation immunotherapies for cancer and infectious diseases, has appointed Dr. Ashok Amin VP of research and development. Dr. Amin's academic career includes positions as director of rheumatology research at the Hospital for Joint Diseases at New York University and director of translational research at the Virginia College of Medicine.

Craig PARKER

NEW DEVELOPMENT VP AT HUMAN GENOME SCIENCES

Human Genome Sciences (HGS), a biotechnology company focused on immunology and oncology, has named Craig Parker senior VP, strategy and corporate development. Partnering with commercial, finance and R&D teams, Mr. Parker is leading future development of HGS's global business strategy, as well as the evaluation and execution of business development opportunities.

Mr. Parker was most recently CEO and co-founder of Vega Therapeutics. He received an MBA from the Stephen M. Ross School of Business at the University of Michigan.

► BIOPHARMACEUTICAL POOL

Paul MERRIGAN

Dr. Mark SUMERAY

AEGERION EXPANDS LEADERSHIP TEAM

Aegerion Pharmaceuticals, a biopharmaceutical company focused on the development and com-

mercialization of novel therapeutics to treat severe lipid disorders, has appointed Paul Merrigan VP of global marketing.

Mr. Merrigan was most recently VP and general manager of neuromuscular diseases at Genzyme.

In other recent moves, Aegerion has named Mark Sumeray, M.D., chief medical officer. Dr. Sumeray joins Aegerion from Bristol-Myers Squibb, where he was VP, cardiovascular/metabolic, U.S. medical.

Frederick GRAFF

MAP PHARMACEUTICALS SELECTS COMMERCIAL HEAD

MAP Pharmaceuticals, a biopharmaceutical company developing and commercializing new therapies to address under-met patient needs in neurology, has appointed Frederick Graff VP, commercial operations.

Mr. Graff is leading the establishment of a commercial sales organization, as well as developing a U.S. launch strategy for MAP's Levadex orally inhaled migraine drug in anticipation of potential approval by the FDA.

He has more than 25 years of experience in commercial sales and marketing of pharmaceutical products, including stints as a senior VP of sales for Sepracor and VP of sales for Vanda Pharmaceuticals.

David MOORE

Dr. Kenneth RUETTIMANN

TRANZYME STRENGTHENS OPERATIONS LEADERSHIP

Tranzyme Pharma, a late-stage biopharmaceutical company focused on upper gastrointestinal motility disorders, has added two executives to its operations management team.

As VP, commercial operations, David Moore is responsible for market development-related activities for Tranzyme's advanced drug candidates, including designing and executing the company's global product strategy. Mr. Moore was most recently group director of Ortho-McNeil Janssen Pharmaceuticals' pain franchise. He received an MBA in marketing from Lehigh University and a graduate degree in health policy from Thomas Jefferson University.

Kenneth Ruettimann, Ph.D., has joined Tranzyme as senior director, manufacturing operations, responsible for managing the chemical and pharmaceutical development strategies for the company's drug candidates.

Dr. Ruettimann most recently served as senior director, API manufacturing at Inspire Pharmaceuticals. He holds an M.S. and a Ph.D. from Purdue University.

► SPECIALTY POOL

Kelly COPELAND

Dr. Evan DICK

Dr. Jim DOWELL

Dr. Tim HENKEL

Dr. Jeffrey SHAVER

Dr. Martin STOGNIEW

Steve TULLMAN

Dr. H. Jeffrey WILKINS

Dr. Lisa WITTMER

YAUPON FORMS NEW MANAGEMENT TEAM

Privately held specialty pharmaceutical company Yaupon Therapeutics has recently made a number of new management team appointments to strengthen the company's foundation and drive momentum as it prepares the NDA submission for its proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early-stage mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL).

Kelly Copeland has been named VP of product strategy. Before joining Yaupon, Ms. Copeland was the VP of business development and product strategy for Ception Therapeutics.

She received an M.S. in health services administration from the University of Michigan.

Evan Dick, Ph.D., has been appointed senior VP of business development. Dr. Dick most recently served as senior VP of discovery medicine and operations at Ception.

He received a Ph.D. from the University at Buffalo, part of the State University of New York system.

Yaupon has named Jim Dowell, Ph.D., VP of biopharmaceutics. Dr. Dowell has more than 15 years of drug development experience, including positions at Ception, Vicuron Pharmaceuticals, Wyeth, and Shire. He holds a Ph.D. from the University of Southern California.

Tim Henkel, M.D., Ph.D., has been named executive VP, head of research and development. Dr. Henkel's experience includes stints as executive VP of research and development at Ception, chief medical officer of Vicuron, and a VP at Glaxo-SmithKline.

Yaupon has appointed Jeffrey Shaver, Ph.D., VP of project management and operations. Dr. Shaver was previously VP of project management, alliances, and information technology for Ception. He earned an M.S. from Purdue University and a Ph.D. from the Massachusetts Institute of Technology.

Martin Stogniew, Ph.D., has been appointed VP

of pharmaceutical sciences. Before joining Yaupon, Dr. Stogniew was executive VP, chief technology officer of Prestwick Pharmaceuticals. Dr. Stogniew received a Ph.D. in medicinal chemistry from the University of Maryland.

Steve Tullman has been named chairman and CEO. Mr. Tullman also serves as the Chairman of Vicept Therapeutics, and before joining Yaupon, he was co-founder, president, and CEO of Ception.

H. Jeffrey Wilkins, M.D., has been appointed chief medical officer. Dr. Wilkins' most recent roles include VP of worldwide clinical development, oncology and immunology of Cephalon and senior VP of clinical development of Ception.

Yaupon has appointed Lisa Wittmer, Ph.D., VP of regulatory affairs. Before joining Yaupon, Dr. Wittmer was VP and general manager of the emerging products business unit at Shire Pharmaceuticals.

Dr. Wittmer received an M.S. in chemistry and a Ph.D. in neuropharmacology and molecular biophysics from Washington University.

► AGENCY POOL

Dr. Himani KULKARNI

Lauren LETELLIER

Denise POWELL

WCG BOLSTERS HEALTHCARE EXPERTISE

WCG, a global independent company offering integrated creative, interactive, and marketing communications services, has hired three senior professionals to broaden its expertise within its core healthcare market.

Himani Kulkarni, M.D., has been named group medical director, strengthening WCG's medical and scientific rigor and working with the agency's leadership team to build out its advisory council across all key therapeutic areas. Dr. Kulkarni has worked at several leading healthcare agencies for both WPP and Euro, where she served as lead

medical director on multiple global assignments across a range of therapeutic categories.

Lauren Letellier has joined WCG as managing director. Ms. Letellier most recently served as senior partner, managing director for TogoRun.

Denise Powell has been appointed group director. Ms. Powell was previously senior director of corporate communications at Threshold Pharmaceuticals.

Helen OSTROWSKI

FORMER PORTER NOVELLI CEO JOINS APCO WORLDWIDE

Helen Ostrowski has joined independent global communications consultancy APCO Worldwide as a senior advisor. Ms. Ostrowski, most recently chairman and CEO of Porter Novelli, brings to APCO more than 40 years of experience working with CEOs, chief communication officers, and other c-suite executives from major healthcare companies and associations to successfully position their companies and products to internal and external constituencies.

► CRO POOL

Dr. Michael (Mike) BOYD

NOVELLA CLINICAL NAMES CLINICAL REPORTING HEAD

Novella Clinical has appointed Michael (Mike) Boyd, Ph.D., global head of clinical reporting, with executive oversight for all biostatistics and SAS programming activities within the full-service CRO. In leading Novella's existing clinical reporting team, Dr. Boyd has responsibility for Novella's four U.S. offices as well as operations in the United Kingdom and Russia.

Dr. Boyd joins Novella from INC Research, where he served as senior director, global biostatistics. He received a Ph.D. in biostatistics from the University of North Carolina at Chapel Hill.

John DAVIS II

Dr. Martine DEHLINGER-KREMER

Marguerite (Peggy) DORAN

Dr. Lexy KELLY

Debra MARSHALL

RPS EXPANDS MANAGEMENT ROSTER

ReSearch Pharmaceutical Services (RPS), a next-generation CRO that provides global Phase II-IV clinical development solutions to the biopharmaceutical and medical device industries, has made a number of key additions to its operational and senior management team.

John Davis II has been appointed chief information officer (CIO) and executive VP, clinical systems. Mr. Davis previously served as senior VP and CIO at the American Board of Internal Medicine and executive VP and CIO at Omnicare Clinical Research.

Martine Dehlinger-Kremer, Ph.D., has joined RPS as VP, global regulatory affairs. Dr. Dehlinger-Kremer was most recently VP of global regulatory affairs and global medical affairs at Theorem Clinical Research.

Marguerite (Peggy) Doran has been named executive director, R&D business operations management.

Ms. Doran has more than 25 years of pharmaceutical industry experience, including 18 years of experience in contract negotiation and management, implementation of sourcing strategies, contract optimization, and process improvements, as well as vendor relationship management and governance programs.

Lexy Kelley, M.D., has joined RPS as medical director, immunology development services, from UCB Pharma, where she served as an associate medical director.

Debra Marshall has been named VP, clinical programs and global site management. Ms. Marshall joins RPS from Pfizer, where she was most recently assistant VP, U.S. global site management. **PV**